Literature DB >> 15787785

Current status of ABO-incompatible kidney transplantation in children.

S Shishido1, A Hasegawa.   

Abstract

This article reviews the current status of ABO-incompatible kidney transplantation in the pediatric population. ABO blood type incompatibility between a donor and recipient was generally considered a contraindication to kidney transplantation because of the associated high risk for hyperacute rejection. However, due to a severe shortage of suitable cadaveric allografts, much effort has been made over the last decade to investigate whether successful and effective kidney transplantation is possible across the ABO blood group barrier. At present, ABO-incompatible kidney transplantation has been shown to be a valid alternative even for children with end stage renal disease. In this review, we will discuss protocols available for successfully performing ABO-incompatible kidney transplantation in children: (1) pre-transplant extracorporeal immunomodulation with removal of pre-existing anti-A and/or anti-B antibodies; (2) immunosuppressive therapy and anti-rejection therapy; (3) splenectomy and the associated infectious complication in asplenic children. Also, we will speculate regarding the mechanisms underlying accommodation following transplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15787785     DOI: 10.1111/j.1399-3046.2004.00234.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  2 in total

1.  ABO-incompatible pediatric kidney transplantation without antibody removal.

Authors:  Takeshi Kawamura; Yuko Hamasaki; Yusuke Takahashi; Junya Hashimoto; Mai Kubota; Masaki Muramatu; Yoshihiro Itabashi; Yoji Hyodo; Yasushi Ohashi; Atushi Aikawa; Ken Sakai; Seiichiro Shishido
Journal:  Pediatr Nephrol       Date:  2019-10-31       Impact factor: 3.714

2.  Incidence of malignancy after pediatric kidney transplantation: a single-center experience over the past three decades in Japan.

Authors:  Yujiro Aoki; Hiroyuki Satoh; Yuko Hamasaki; Riku Hamada; Ryoko Harada; Hiroshi Hataya; Kenji Ishikura; Masaki Muramatsu; Seiichiro Shishido; Ken Sakai
Journal:  Clin Exp Nephrol       Date:  2021-09-27       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.